14465 results in Neurology and Clinical Neuroscience
31 - Best Practices for Clinical Trials during COVID-19
- from Section 3 - Alzheimer’s Disease Clinical Trials
-
-
- Book:
- Alzheimer's Disease Drug Development
- Published online:
- 03 March 2022
- Print publication:
- 31 March 2022, pp 354-360
-
- Chapter
- Export citation
28 - The Role of Regulatory Agencies in Alzheimer’s Disease Drug Development
- from Section 3 - Alzheimer’s Disease Clinical Trials
-
-
- Book:
- Alzheimer's Disease Drug Development
- Published online:
- 03 March 2022
- Print publication:
- 31 March 2022, pp 319-332
-
- Chapter
- Export citation
11 - Phase 1 Trials in Alzheimer’s Disease Drug Development
- from Section 3 - Alzheimer’s Disease Clinical Trials
-
-
- Book:
- Alzheimer's Disease Drug Development
- Published online:
- 03 March 2022
- Print publication:
- 31 March 2022, pp 135-149
-
- Chapter
- Export citation
32 - Development of Fluid Biomarkers for Alzheimer’s Disease
- from Section 4 - Imaging and Biomarker Development in Alzheimer’s Disease Drug Discovery
-
-
- Book:
- Alzheimer's Disease Drug Development
- Published online:
- 03 March 2022
- Print publication:
- 31 March 2022, pp 361-374
-
- Chapter
- Export citation
Section 3 - Alzheimer’s Disease Clinical Trials
-
- Book:
- Alzheimer's Disease Drug Development
- Published online:
- 03 March 2022
- Print publication:
- 31 March 2022, pp 135-360
-
- Chapter
- Export citation
12 - The Importance of Phase 2 in Drug Development for Alzheimer’s Disease
- from Section 3 - Alzheimer’s Disease Clinical Trials
-
-
- Book:
- Alzheimer's Disease Drug Development
- Published online:
- 03 March 2022
- Print publication:
- 31 March 2022, pp 150-161
-
- Chapter
- Export citation
Section 2 - Non-clinical Assessment of Alzheimer’s Disease Candidate Drugs
-
- Book:
- Alzheimer's Disease Drug Development
- Published online:
- 03 March 2022
- Print publication:
- 31 March 2022, pp 73-134
-
- Chapter
- Export citation
13 - Alzheimer’s Disease Drug Development in Pharmaceutical Companies
- from Section 3 - Alzheimer’s Disease Clinical Trials
-
-
- Book:
- Alzheimer's Disease Drug Development
- Published online:
- 03 March 2022
- Print publication:
- 31 March 2022, pp 162-169
-
- Chapter
- Export citation
24 - The Use and Development of Clinical Measures of Alzheimer’s Disease Trials
- from Section 3 - Alzheimer’s Disease Clinical Trials
-
-
- Book:
- Alzheimer's Disease Drug Development
- Published online:
- 03 March 2022
- Print publication:
- 31 March 2022, pp 281-291
-
- Chapter
- Export citation
7 - Role of Animal Models in Alzheimer’s Disease Drug Development
- from Section 2 - Non-clinical Assessment of Alzheimer’s Disease Candidate Drugs
-
-
- Book:
- Alzheimer's Disease Drug Development
- Published online:
- 03 March 2022
- Print publication:
- 31 March 2022, pp 73-94
-
- Chapter
- Export citation
Section 5 - Academic Drug-Development Programs
-
- Book:
- Alzheimer's Disease Drug Development
- Published online:
- 03 March 2022
- Print publication:
- 31 March 2022, pp 429-454
-
- Chapter
- Export citation
35 - Pharmacogenetics in Alzheimer’s Disease Drug Discovery and Personalized Treatment
- from Section 4 - Imaging and Biomarker Development in Alzheimer’s Disease Drug Discovery
-
-
- Book:
- Alzheimer's Disease Drug Development
- Published online:
- 03 March 2022
- Print publication:
- 31 March 2022, pp 404-417
-
- Chapter
- Export citation
23 - Globalization of Alzheimer’s Disease Clinical Trials
- from Section 3 - Alzheimer’s Disease Clinical Trials
-
-
- Book:
- Alzheimer's Disease Drug Development
- Published online:
- 03 March 2022
- Print publication:
- 31 March 2022, pp 275-280
-
- Chapter
- Export citation
47 - Introduction to Venture Capital in Alzheimer’s Disease Drug Development
- from Section 7 - Funding and Financing Alzheimer’s Disease Drug Development
-
-
- Book:
- Alzheimer's Disease Drug Development
- Published online:
- 03 March 2022
- Print publication:
- 31 March 2022, pp 524-532
-
- Chapter
- Export citation
Dedication
-
- Book:
- Alzheimer's Disease Drug Development
- Published online:
- 03 March 2022
- Print publication:
- 31 March 2022, pp v-vi
-
- Chapter
- Export citation
37 - Institutional Review Boards and Oversight of Alzheimer’s Disease Trials
- from Section 5 - Academic Drug-Development Programs
-
-
- Book:
- Alzheimer's Disease Drug Development
- Published online:
- 03 March 2022
- Print publication:
- 31 March 2022, pp 429-436
-
- Chapter
- Export citation
Index
-
- Book:
- Alzheimer's Disease Drug Development
- Published online:
- 03 March 2022
- Print publication:
- 31 March 2022, pp 544-554
-
- Chapter
- Export citation
27 - The Role of the Contract Research Organization in Alzheimer’s Disease: The Vital Link in the Clinical Drug-Development Program
- from Section 3 - Alzheimer’s Disease Clinical Trials
-
-
- Book:
- Alzheimer's Disease Drug Development
- Published online:
- 03 March 2022
- Print publication:
- 31 March 2022, pp 309-318
-
- Chapter
- Export citation
29 - Alzheimer’s Disease Clinical Trial Study Partners
- from Section 3 - Alzheimer’s Disease Clinical Trials
-
-
- Book:
- Alzheimer's Disease Drug Development
- Published online:
- 03 March 2022
- Print publication:
- 31 March 2022, pp 333-342
-
- Chapter
- Export citation
15 - ATRI and ACTC: Academic Programs to Accelerate Alzheimer’s Disease Drug Development
- from Section 3 - Alzheimer’s Disease Clinical Trials
-
-
- Book:
- Alzheimer's Disease Drug Development
- Published online:
- 03 March 2022
- Print publication:
- 31 March 2022, pp 177-189
-
- Chapter
- Export citation